Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1108553.RAYBd2IdaQJwJj_NfOh6knEH8NU4n_RpSnqqsO6By4asg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1108553.RAYBd2IdaQJwJj_NfOh6knEH8NU4n_RpSnqqsO6By4asg130_assertion type Assertion NP1108553.RAYBd2IdaQJwJj_NfOh6knEH8NU4n_RpSnqqsO6By4asg130_head.
- NP1108553.RAYBd2IdaQJwJj_NfOh6knEH8NU4n_RpSnqqsO6By4asg130_assertion description "[Patient proportions with TP53 defects at diagnosis or before first therapy were reported within the range 5-15 %, but they increase dramatically in pretreated cohorts (reported up to 44 %), and also in patients with Richter transformation (50 % harbor TP53 defects).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1108553.RAYBd2IdaQJwJj_NfOh6knEH8NU4n_RpSnqqsO6By4asg130_provenance.
- NP1108553.RAYBd2IdaQJwJj_NfOh6knEH8NU4n_RpSnqqsO6By4asg130_assertion evidence source_evidence_literature NP1108553.RAYBd2IdaQJwJj_NfOh6knEH8NU4n_RpSnqqsO6By4asg130_provenance.
- NP1108553.RAYBd2IdaQJwJj_NfOh6knEH8NU4n_RpSnqqsO6By4asg130_assertion SIO_000772 24014294 NP1108553.RAYBd2IdaQJwJj_NfOh6knEH8NU4n_RpSnqqsO6By4asg130_provenance.
- NP1108553.RAYBd2IdaQJwJj_NfOh6knEH8NU4n_RpSnqqsO6By4asg130_assertion wasDerivedFrom befree-2016 NP1108553.RAYBd2IdaQJwJj_NfOh6knEH8NU4n_RpSnqqsO6By4asg130_provenance.
- NP1108553.RAYBd2IdaQJwJj_NfOh6knEH8NU4n_RpSnqqsO6By4asg130_assertion wasGeneratedBy ECO_0000203 NP1108553.RAYBd2IdaQJwJj_NfOh6knEH8NU4n_RpSnqqsO6By4asg130_provenance.